Uroprin

Quick links to important sections

Uroprin

Method of action: Analgesic, Analgetic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uroprin

Uroprin: Product Identity and Function

The foundational identity of Uroprin, a trade name for the compound Phenazopyridine Hydrochloride, is summarized below, providing essential facts about its classification and purpose in a concise format.

Property Description
Active ingredient Phenazopyridine Hydrochloride
Form Tablet or Capsule
Pharmacological class Urinary Analgesic, Local Anesthetic
Common use Symptomatic relief of lower urinary tract discomfort
Origin Synthetic (Azo Dye Compound)

What Type of Medicine is Uroprin?

Uroprin is a synthetic medicinal entity primarily classified as a urinary analgesic, a drug specifically designed to relieve localized discomfort in the urinary tract. Its sole active compound is Phenazopyridine Hydrochloride, which falls into the chemical class of azo dyes.

This formulation is available for the oral route of administration as a single-ingredient product, typically prepared in a tablet or capsule form. The active ingredient is rapidly excreted by the kidneys, which is key to its targeted action. It is crucial to understand that Phenazopyridine is not an antibiotic and offers no antimicrobial action; its function is entirely analgesic.

What is the Purpose of a Urinary Analgesic?

The primary purpose of Uroprin is to provide symptomatic relief from the pain, burning, urgency, and discomfort associated with irritation of the lower urinary system. This function is intended for easing discomfort that might otherwise disrupt daily activities, such as during the recovery period from an outpatient medical procedure.

The therapeutic effect is achieved by the active compound acting as a local anesthetic directly on the urinary tract mucosa. As the drug is quickly excreted by the kidneys into the urine, it comes into direct contact with the irritated lining, producing a surface-level numbing effect. This highly localized action is consistent with its role as a unique analgesic for treating bladder pain, ensuring the drug effectively diminishes localized discomfort without engaging widespread systemic effects.

Regulatory References

  1. MedlinePlus

What side effects are possible with Uroprin?

Possible Side Effects and Safety Information

The safety profile of Uroprin (Phenazopyridine Hydrochloride) is officially documented across several organ systems, with specific attention paid to hematological and excretory functions, as detailed in regulatory documents.

Adverse Reaction Groupings

The officially listed adverse reactions are generally grouped by the affected body system, including Gastrointestinal Disorders (such as nausea, vomiting, or stomach upset), Nervous System Disorders (including headache or dizziness), and Skin and Subcutaneous Tissue Disorders (like rash and itching). The incidence frequency for many post-marketing adverse events is documented as Not Known in regulatory labeling.

Serious Adverse Reactions and Organ Systems

While uncommon, the label documents the potential for serious adverse reactions, primarily associated with higher doses or impaired drug excretion. These include severe Hematologic effects like methemoglobinemia and hemolytic anemia. Furthermore, Hepatic Toxicity (hepatitis) and Acute Renal Failure are documented risks, which necessitate cautious use.

Safety Constraints and Considerations

The regulatory profile places specific contraindications on the use of Uroprin. It is strictly limited in patients with pre-existing severe renal insufficiency or severe hepatic disease, as impaired function can lead to drug accumulation and increased risk of toxicity. The label specifies that when used adjunctively with an antibacterial for a urinary tract infection, use should not exceed two days. The drug’s nature as an azo dye results in an expected and harmless reddish-orange discoloration of the urine, but a yellowish tinge to the skin or eyes (jaundice) may signal drug accumulation, requiring prompt discontinuance of the medicine.

Overdose and Emergency Response

The official overdose profile for Uroprin (Phenazopyridine Hydrochloride) centers on the risk of severe hematological and organ toxicity, requiring immediate action as mandated by regulatory authorities.

Documented Manifestations and Severe Outcomes

Overdose is characterized by the potential for methemoglobinemia, a hematological condition that impairs the blood's oxygen-carrying capacity and can lead to symptoms like cyanosis. Other serious documented findings include hemolytic anemia (red blood cell destruction). Life-threatening outcomes formally described in regulatory labeling are acute renal failure and hepatic toxicity (liver damage). Accumulation of the drug in high-exposure cases may also result in the yellowing of the eyes or skin pigmentation, which may signal drug accumulation.

Required Emergency Actions

Official regulatory guidance strictly mandates that individuals must seek professional assistance or contact a poison control center immediately upon suspicion of an overdose. The need for urgent medical care is driven by the potential for severe, life-threatening outcomes. Specific procedures in management may include symptomatic and supportive treatment, with administration of Methylene blue or Ascorbic acid listed for the management of methemoglobinemia. Hospital monitoring of blood methemoglobin levels and renal function is required. Regulatory documents also note that patients with impaired renal function or G-6-PD deficiency are at heightened risk of severe toxicity.

Therapeutic Uses of Uroprin

Phenazopyridine (Uroprin) is a urinary analgesic used to provide symptomatic relief from acute discomfort in the lower urinary tract.


What Uroprin Treats: Main Uses and Benefits

Phenazopyridine is relevant in contexts marked by increased discomfort related to inflammatory or irritative states of the lower urinary tract. It is indicated for the symptomatic relief of discomfort arising from irritation, including the pain and burning sensation (dysuria) that may become pronounced during urination, along with associated symptoms like urinary urgency and increased frequency. The compound is used to ease distressing symptoms that generally arise from conditions such as cystitis, urethritis, prostatitis, or irritation following urological procedures. It contributes to easing distress during episodes of heightened discomfort.

“Applied in scenarios where additional management of discomfort is required, Uroprin may assist with easing the overall symptom burden.”

This supportive relief is commonly used in contexts involving acute Urinary Tract Infections (UTIs) or following procedural interventions like catheterization. The medication may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Symptomatic support for Acute Lower Urinary Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Uroprin?

Absolute Contraindications and Restrictions

The eligibility for Uroprin (Phenazopyridine Hydrochloride) is strictly limited by regulatory authorities based on organ function. The medicine is contraindicated in patients diagnosed with renal insufficiency or impaired kidney function, and in those with severe liver disease or severe hepatitis, due to the risk of drug accumulation. Absolute non-eligibility also applies to individuals with known hypersensitivity to the active ingredient. Pyelonephritis of pregnancy is a specific, formal contraindication.

Age and Conditional Use

Use is established for adults and adolescents aged 12 years and older. However, the safety and efficacy of the drug have not been established in children under 6 years. For older adults, caution is advised due to the common decline in renal function. Use is conditional for those with G-6-PD deficiency, requiring cautious administration.

Pregnancy and Lactation

During pregnancy, the use of the medicine is conditional, permitted only if the benefit clearly outweighs the risk. For lactating women, regulatory guidance states that a decision must be made to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Uroprin (Phenazopyridine Hydrochloride) details specific interaction patterns concerning co-administered medicines, duration of use, and certain laboratory procedures.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Phenazopyridine co-administration with Trimethoprim/Sulfamethoxazole may lead to an increase in the plasma concentrations of both the antibacterial components and Phenazopyridine itself. This is an officially documented exposure-altering interaction.

Caution is advised with agents that are also associated with methemoglobinemia. Combining such agents with Phenazopyridine increases the pharmacodynamic risk and severity of this specific hematologic condition due to an additive toxic effect.

Administration and Procedural Constraints

When utilized concurrently with an antibacterial agent for a urinary tract infection, Phenazopyridine administration is subject to a regulatory constraint and must not exceed 2 days.

Administration is advised with or following food or after eating a snack to manage potential gastrointestinal upset.

Due to its classification as an azo dye, Phenazopyridine interferes with laboratory tests. It may cause inaccurate results in urinalysis methods based on color reactions, such as tests for bilirubin, glucose, and ketones.

Population-Specific Notes

In patients with impaired renal function or advanced age, there is an increased risk of Phenazopyridine accumulation due to decreased renal excretion. Cautious use is also noted in patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency due to a heightened potential for hemolytic anemia.

Mechanism of Action

How Uroprin Works

Receptor-Level Modulation of Bladder Signals

Uroprin functions as a competitive antagonist by selectively targeting and blocking muscarinic M3 receptors located on the detrusor smooth muscle cells of the bladder wall and associated efferent nerves . This action directly prevents the key neurotransmitter, acetylcholine (ACh), from binding and activating these receptors, thereby interrupting the neurochemical signal for muscle excitation.

Inhibition of Parasympathetic Contraction Pathway

The drug's mechanism effectively inhibits the final molecular step of the parasympathetic signaling pathway that controls the bladder's contractile state. By dampening these nerve-driven signals, Uroprin directly influences the core mechanism underlying detrusor muscle tone, resulting in smooth muscle relaxation and a decrease in muscle excitability.

Physiological Consequence: Capacity and Pressure

The mechanism influences bladder mechanoreceptors and muscle compliance, resulting in the modulation of the bladder's filling pressure profile and capacity parameters. These resulting physiological effects describe the drug's influence on the electromechanical behavior of the lower urinary tract.

Dosage and Administration Information

Uroprin, whose active ingredient is Phenazopyridine Hydrochloride, is prescribed for oral administration only, typically provided as tablets in 100 mg and 200 mg unit strengths. The usage is structured around a precise, short-term regimen.

The standard adult dosing schedule, which also applies to children 12 years of age and older, is 200 mg per dose, taken three times daily. To mitigate the potential for stomach discomfort, each dose is typically administered with or immediately after meals or a snack. This administration principle ensures proper intake conditions are met.

A crucial constraint on administration is the course duration, which must not exceed 2 days when the medicine is used concomitantly with an antibacterial agent for the treatment of a urinary tract infection. The drug should be discontinued promptly once the patient's acute symptoms are adequately managed, aligning with its role as a supportive measure.

As a high-level administration note, Uroprin is an azo dye compound and will cause a distinct reddish-orange discoloration of the urine—a normal expected consequence that can stain soft contact lenses and clothing. Additionally, a key procedural step is the mandatory cessation of the drug if any yellowish tinge is observed on the skin or in the whites of the eyes (sclerae). This instruction is critical because a yellowish tint may indicate an accumulation of the medicine due to impaired renal excretion, requiring immediate interruption of the regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for GLP-1 Receptor Agonists


Evidence for use in Type 2 Diabetes Mellitus

Research examined GLP-1 Receptor Agonists in adults with Type 2 Diabetes Mellitus (T2DM) using short-term and intermediate-term randomized controlled trials. Findings describe measurements of lower mean HbA1c values and tracked measurements of weight reduction. Studies monitored the incidence of low blood sugar events (hypoglycemia), which were generally low when the treatment was not combined with certain other diabetes medications. Uncertainty remains regarding the long-term stability of these changes and specific microvascular outcomes beyond one to two years.


Evidence for use in Cardiovascular Risk Reduction

Large, long-term Cardiovascular Outcome Trials (CVOTs) explored MACE (Major Adverse Cardiovascular Events) in high-risk T2DM populations. Data show patterns related to a lower reported incidence of the composite MACE outcome and a lower number of reported heart failure hospitalizations in the study arms. Findings describe group patterns, but reported measurements related to mortality varied across trials. The mechanism for these patterns and data for very low-risk populations are still uncertain.


Evidence for use in Chronic Weight Management

Dedicated placebo-controlled trials explored weight management in adults with obesity or overweight with related comorbidities. Research highlights greater mean percentage weight reductions and a higher proportion of participants reaching pre-defined weight loss thresholds. Gastrointestinal events were frequently observed. Limited information exists on long-term weight maintenance and related functional outcomes beyond approximately 18 months.


Evidence for use in Chronic Kidney Disease Progression

Prespecified analyses from cardiovascular trials examined CKD progression in T2DM patients. Findings describe measurements of a slower rate of eGFR decline and observations of lower mean UACR values. Uncertainty remains regarding the long-term functional consequences, especially in patients with advanced CKD.


Long-term Studies and Follow-up Duration

While some large studies have tracked participants for up to five years, many initial trials focused on measuring outcomes within one year or less. Long-term effects across all indications are not fully established, and evidence regarding the persistence of observed changes over many years is limited.


Evidence in Special Populations

Data for certain groups remain insufficient, including frail older adults and patients with severe comorbidities outside of heart or kidney issues. Research exploring short-term symptom changes in pediatric populations is emerging, but follow-up durations were limited in these initial studies.


What is Still Uncertain About GLP-1 Receptor Agonists

Research gaps include a lack of direct head-to-head comparative studies and mixed data for low-risk populations. The safety profile in patients with a history of certain thyroid-related tumors is an ongoing area of research. Research highlights that the results apply only to the populations studied and the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Uroprin (FAQ)


Q: Do you need a prescription to get Uroprin?

A: Uroprin's active ingredient, Phenazopyridine Hydrochloride, is available in both over-the-counter (OTC) and prescription strengths, depending on the dosage unit. Official documents indicate that patients may encounter either OTC or prescription versions depending on the specific product formulation.

Q: How long does it usually take to feel the effects of Uroprin?

A: Official information indicates that the active ingredient is rapidly excreted by the kidneys and provides a local analgesic effect in the urinary tract. This action is intended to promptly relieve symptoms like pain and burning. While the exact onset time is not consistently specified in all regulatory documents, its rapid excretion pattern is consistent with quick relief.

Q: Can Uroprin be used by people who have diabetes?

A: Uroprin is not contraindicated for people with diabetes. However, official information advises that it may interfere with certain laboratory tests. Because of its nature as an azo dye, it may cause a false positive result for glucose (sugar) in the urine when colorimetric tests are used. Regulatory guidance recommends informing a healthcare professional about all medications, especially before laboratory work.

Q: What should I do if I miss a dose of Uroprin?

A: Official medication guides generally describe the appropriate procedural steps for handling a missed dose, which typically involves taking it as soon as possible or skipping it if the next dose is near. The guidance is to avoid taking double or extra doses.

Q: Does Uroprin interact with common pain medications like ibuprofen?

A: Regulatory documents state that the interaction of Phenazopyridine Hydrochloride with many other drugs has not been studied in a systematic manner. However, the available medical literature suggests that no significant interactions have been reported. It is standard practice to inform a health professional about all medicines being taken.

Q: What type of research has been done on the benefits of Uroprin?

A: Official documentation indicates that the drug's use is limited to symptomatic relief for no longer than two days when used with an antibacterial, noting a lack of evidence that combined administration provides greater benefit than the antibacterial alone after two days. Its use is focused on providing comfort during the necessary treatment period.

Q: Is Uroprin related to any herbal or natural remedies?

A: Uroprin’s active ingredient, Phenazopyridine Hydrochloride, is a synthetic chemical compound. It is specifically designated as an azo dye compound and is not derived from or related to any herbal or natural remedies.

Q: Does Uroprin interact with blood pressure medications?

A: Official regulatory documents note that systematic interaction studies of Uroprin with many other drugs have not been conducted. While no significant interactions with common blood pressure medications have been widely reported in the medical literature, regulatory guidance recommends informing a healthcare professional about all existing medications. This allows for assessment based on the known pharmacological profile.

Q: Is it okay to take Uroprin if I am already taking an antidepressant?

A: Regulatory documents state that the systematic interaction of Uroprin with many other drugs, including antidepressants, has not been fully studied. No significant drug-drug interactions with this class of medication have been widely reported in the available medical literature. Regulatory guidance recommends consulting a healthcare professional when combining medications.

Q: Does Uroprin have an expiry date that is important to follow?

A: Official safety protocols state that the drug should not be used if the expiration date has passed. Regulatory instructions for safe disposal apply to 'unused or expired product.' These instructions indicate that the expiration date is a necessary measure for maintaining product quality and stability.

Q: Can people who are vegetarian or vegan take Uroprin?

A: The suitability of Uroprin for vegetarian or vegan diets depends on the inactive ingredients used in the specific formulation (tablet or capsule). Patients can check the official inactive ingredients list for components like gelatin, which may be present in capsule forms. Many tablet formulations contain common non-animal-derived components like cellulose and starch.

Q: Does Uroprin have a drug-drug interaction with blood thinners?

A: Regulatory documents state that the interaction of Uroprin with other medications has not been systematically studied in detail. While no significant interactions with anticoagulants (blood thinners) have been widely reported in the medical literature, regulatory guidance recommends informing a health professional about all medications. This allows for assessment based on the known pharmacological profile.

Q: Is it necessary to drink extra water while taking Uroprin?

A: While the core instructions focus on taking the medicine with or immediately after food, the directions for use often recommend taking the dose with a full glass of water. Taking the dose with a full glass of water, as often recommended in the directions for use, supports proper administration.

Q: What is the evidence level for Uroprin's effectiveness?

A: Regulatory documents note that the precise mechanism of action is not fully known, and the drug is indicated only for short-term symptomatic relief. Its effectiveness is established only for easing discomfort (pain, burning, urgency) for a limited duration, typically up to two days, and it is not intended as a cure for underlying conditions.

Q: What is the general recommendation if I experience a rare side effect from Uroprin?

A: Official safety documents advise that patients stop using the drug immediately if they suspect an adverse reaction or if symptoms persist beyond two days. The documentation states that severe reactions, such as a yellowish tinge to the skin or eyes, necessitate prompt contact with a health professional.

Q: Can Uroprin be taken alongside birth control pills?

A: Regulatory documents state that the systematic study of Uroprin's interactions with other drugs is limited. No significant interactions with oral contraceptives (birth control pills) have been widely reported in the available medical literature. Regulatory guidance recommends consulting a healthcare professional when combining medications.

Q: Are there research studies comparing Uroprin to a placebo?

A: Official documentation suggests treatment should not exceed two days because there is a lack of evidence that the combined use with an antibacterial provides greater benefit than the antibacterial alone after two days. This constraint is consistent with the drug's role as a supportive measure.

Q: Why is Uroprin sometimes mentioned alongside medicines for urinary tract infections?

A: Uroprin is compatible with antibacterial therapy and is used to help relieve pain and discomfort during the initial period before the antibacterial therapy can control the infection. It only provides comfort and is not an antibacterial treatment.

Q: Does Uroprin cause drowsiness or affect alertness?

A: Adverse reactions officially listed for Uroprin include dizziness and headache. Regulatory documents advise exercising caution when driving or operating heavy machinery. This is noted because such adverse reactions may affect alertness.

Q: Is it normal for Uroprin to not relieve all of my symptoms?

A: Uroprin is an analgesic indicated only for the symptomatic relief of discomfort and is not a curative treatment. Official guidance states the drug should be discontinued once the acute symptoms are adequately managed, reinforcing its role as a supportive, symptom-relieving measure.

Q: How does the action of Uroprin differ from a general painkiller?

A: Uroprin is classified as a local analgesic, meaning it works specifically on the irritated lining of the urinary tract mucosa to relieve pain. This mechanism is different from general painkillers (systemic analgesics or narcotics) which enter the bloodstream and act throughout the entire body to relieve pain.

Q: What happens if you accidentally take more Uroprin than described in the instructions?

A: Official regulatory documents advise immediately contacting a Poison Control Center or seeking medical help in the event of a suspected overdose. Taking more than the described instructions can lead to serious side effects, including specific blood disorders and potential toxicity to the kidneys.

Q: What are the most commonly reported side effects of Uroprin?

A: The most commonly reported adverse effects are gastrointestinal disturbance, such as stomach upset, as well as headache, dizziness, rash, and itching. It is also an expected, non-harmful consequence of the medicine that the urine will turn a reddish-orange color.

Q: What are the signs that Uroprin is starting to work?

A: The drug is indicated to relieve specific types of discomfort related to the lower urinary tract. The signs that Uroprin is starting to work would be a reduction in the severity of symptoms such as pain, burning sensation, urgency, and frequency.

How should Uroprin be stored and disposed of?

How to Store and Dispose of Uroprin?

Uroprin (Phenazopyridine HCl) must be stored and discarded according to official regulatory labeling to maintain product stability and safety.

Storage Requirements

Mandatory Storage Conditions

Requirement Details
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep in a dry place and protected from light.
Container Keep in the original container, tightly closed, and using a child-resistant closure.
Safety Must be kept out of the reach of children.
Prohibited Do not freeze and avoid excessive heat or moisture.

Disposal Instructions

Unused or expired product should be discarded primarily through a drug take-back program. If a take-back option is unavailable, the product must be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container for household trash disposal. The product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uroprin found in:

A-Z Index: